A phase I single dose developmental study investigating the tolerability, pharmacokinetics and pharmacodynamics of controlled-release anagrelide in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
Price : $35 *
At a glance
- Drugs Anagrelide (Primary)
- Indications Essential thrombocythaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 13 Jun 2016 Combined safety data from five phase I trials and a phase II trial published in a Galena Biopharma media release.
- 19 May 2016 Combined safety data from five phase I trials and a phase II trial will be presented at the European Hematology Association 21st Congress, according to a Galena Biopharma media release.
- 07 Feb 2014 New trial record